NCT06496269

Brief Summary

Graft microvascular inflammation poses a significant challenge to successful kidney transplantation due to its heterogeneous clinical presentation. There is a critical need to unravel the clinical significance of newly defined allograft microvascular inflammation phenotypes in the Banff 2022 classification and assess the implications of these new phenotypes on kidney transplant precision diagnostics and patient risk stratification.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2023

Shorter than P25 for all trials

Geographic Reach
5 countries

19 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2023

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 3, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 11, 2024

Completed
Last Updated

July 11, 2024

Status Verified

July 1, 2024

Enrollment Period

12 months

First QC Date

July 3, 2024

Last Update Submit

July 3, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Microvascular inflammation-related diagnoses according to the Banff 2022 Classification

    March 2004 to December 2023

  • Kidney allograft loss

    March 2004 to December 2023

Secondary Outcomes (2)

  • Transplant glomerulopathy

    March 2004 to December 2023

  • (Recurrent) antibody-mediated rejection episode

    March 2004 to December 2023

Interventions

No intervention

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Kidney transplant recipients of all sexes recruited in observational studies performed in Europe and United States, with at least one kidney biopsy performed with all the relevant data to provide a diagnosis according to the 2019 and 2022 Banff classification, including clinical data (recipient and donor's age, sex and transplant characteristics).

You may qualify if:

  • Kidney transplant recipients, with at least one kidney transplant biopsy performed, assessed with the Banff classification.

You may not qualify if:

  • Missing data for a rejection-related diagnosis according to the 2019 and 2022 Banff classification.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (19)

Pediatric Nephrology, UCLA Mattel Children's Hospital

Los Angeles, California, 90095, United States

Location

Division of Pediatric Nephrology, Children's Pediatric Institute

Atlanta, Georgia, 30329, United States

Location

Division of Pediatric Nephrology, Children's Mercy Hospital

Kansas City, Missouri, 64108, United States

Location

Acute Dialysis Units, Pediatric Kidney Transplant

Charleston, South Carolina, 29425, United States

Location

Division of Pediatric Nephrology and Hypertension, Le Bonheur Children's Hospital

Memphis, Tennessee, 38103, United States

Location

Department of Pediatrics, Seattle Children's Hospital

Seattle, Washington, 98105, United States

Location

Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health

Madison, Wisconsin, 53705, United States

Location

Bordeaux University Hospital, Department of Nephrology, Transplantation, Dialysis and Apheresis

Bordeaux, France

Location

Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon

Lyon, France

Location

Department of Nephrology, Centre Hospitalier Universitaire de Montpellier

Montpellier, France

Location

Nantes University Hospital, Department of Nephrology

Nantes, France

Location

Division of Pediatric Nephrology, Necker Hospital, AP-HP

Paris, France

Location

Division of Pediatric Nephrology, Robert Debré Hospital, AP-HP

Paris, France

Location

Kidney Transplant Department, Necker Hospital, Assistance Publique - Hôpitaux de Paris

Paris, France

Location

Kidney Transplant Department, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris

Paris, France

Location

Department of Nephrology-Dialysis-Transplantation, Centre Hospitalier Universitaire de Toulouse

Toulouse, France

Location

Department of Nephrology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Berlin Institute of Health

Berlin, Germany

Location

Department of Nephrology and Kidney Transplantation, Vall d'Hebrón University Hospital

Barcelona, Spain

Location

Division of Abdominal and Transplantation Surgery, Department of Surgery, Geneva University Hospitals,

Geneva, Switzerland

Location

Related Publications (1)

  • Sablik M, Sannier A, Raynaud M, Goutaudier V, Divard G, Astor BC, Weng P, Smith J, Garro R, Warady BA, Zahr RS, Twombley K, Dharnidharka VR, Dandamudi RS, Fila M, Huang E, Sellier-Leclerc AL, Tonshoff B, Rabant M, Verine J, Del Bello A, Berney T, Boyer O, Catar RA, Danger R, Giral M, Yoo D, Girardin FR, Alsadi A, Gourraud PA, Morelon E, Le Quintrec M, Try M, Villard J, Zhong W, Bestard O, Budde K, Chauveau B, Couzi L, Brouard S, Hogan J, Legendre C, Anglicheau D, Aubert O, Kamar N, Lefaucheur C, Loupy A. Microvascular Inflammation of Kidney Allografts and Clinical Outcomes. N Engl J Med. 2025 Feb 20;392(8):763-776. doi: 10.1056/NEJMoa2408835. Epub 2024 Oct 24.

Study Officials

  • Alexandre Loupy

    Paris Institute for Transplantation and Organ Regeneration

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 3, 2024

First Posted

July 11, 2024

Study Start

January 1, 2023

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

July 11, 2024

Record last verified: 2024-07

Locations